Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (131-140 of 223) with videos related to

Pageof 23
Sort By:
Oncotarget|January 12, 2023
Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaDavid King, Xiao Dun Li, Gilberto S Almeida, et al.
Pigment Cell & Melanoma Research|May 15, 2012
Genomic characterisation of acral melanoma cell linesSimon J Furney, Samra Turajlic, Kerry Fenwick, et al.
Genome Biology|October 25, 2011
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencingDavid Sims, Ana M Mendes-Pereira, Jessica Frankum, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Genome Research|December 21, 2011
Whole genome sequencing of matched primary and metastatic acral melanomasSamra Turajlic, Simon J Furney, Maryou B Lambros, et al.
The Journal of Pathology|November 21, 2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorLouise J Barber, Shahneen Sandhu, Lina Chen, et al.
Nature|April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyHannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Cancer Discovery|March 30, 2013
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCNLynn Bjerke, Alan Mackay, Meera Nandhabalan, et al.
Pageof 23

Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Oncotarget|January 12, 2023
Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaDavid King, Xiao Dun Li, Gilberto S Almeida, et al.
Pigment Cell & Melanoma Research|May 15, 2012
Genomic characterisation of acral melanoma cell linesSimon J Furney, Samra Turajlic, Kerry Fenwick, et al.
Genome Biology|October 25, 2011
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencingDavid Sims, Ana M Mendes-Pereira, Jessica Frankum, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Genome Research|December 21, 2011
Whole genome sequencing of matched primary and metastatic acral melanomasSamra Turajlic, Simon J Furney, Maryou B Lambros, et al.
The Journal of Pathology|November 21, 2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorLouise J Barber, Shahneen Sandhu, Lina Chen, et al.
Nature|April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyHannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Oncogene|July 26, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variantStephen J Pettitt, Nan Shao, Diana Zatreanu, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
Cancer Discovery|March 30, 2013
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCNLynn Bjerke, Alan Mackay, Meera Nandhabalan, et al.
Pageof 23